NO990668L - IL-8 reseptor antagonister - Google Patents

IL-8 reseptor antagonister

Info

Publication number
NO990668L
NO990668L NO990668A NO990668A NO990668L NO 990668 L NO990668 L NO 990668L NO 990668 A NO990668 A NO 990668A NO 990668 A NO990668 A NO 990668A NO 990668 L NO990668 L NO 990668L
Authority
NO
Norway
Prior art keywords
receptor antagonists
antagonists
receptor
Prior art date
Application number
NO990668A
Other languages
English (en)
Other versions
NO312458B1 (no
NO990668D0 (no
Inventor
Deborah Lynn Bryan
John Gerald Gleason
Katherine L Widdowson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO990668D0 publication Critical patent/NO990668D0/no
Publication of NO990668L publication Critical patent/NO990668L/no
Publication of NO312458B1 publication Critical patent/NO312458B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO19990668A 1996-08-15 1999-02-12 IL-8-reseptor antagonister, fremgangsmåte for fremstilling derav og farmasöytisk preparat NO312458B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2341496P 1996-08-15 1996-08-15
PCT/US1997/014581 WO1998006397A1 (en) 1996-08-15 1997-08-15 Il-8 receptor antagonists

Publications (3)

Publication Number Publication Date
NO990668D0 NO990668D0 (no) 1999-02-12
NO990668L true NO990668L (no) 1999-04-12
NO312458B1 NO312458B1 (no) 2002-05-13

Family

ID=21814968

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19990668A NO312458B1 (no) 1996-08-15 1999-02-12 IL-8-reseptor antagonister, fremgangsmåte for fremstilling derav og farmasöytisk preparat
NO20016067A NO314301B1 (no) 1996-08-15 2001-12-12 Fremgangsmåte for fremstilling av IL-8-reseptor-antagonister

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20016067A NO314301B1 (no) 1996-08-15 2001-12-12 Fremgangsmåte for fremstilling av IL-8-reseptor-antagonister

Country Status (18)

Country Link
US (1) US6204294B1 (no)
EP (1) EP0929302A4 (no)
JP (1) JP2000516619A (no)
KR (1) KR20000030003A (no)
CN (1) CN1152675C (no)
AR (1) AR008290A1 (no)
AU (1) AU723816B2 (no)
BR (1) BR9711140A (no)
CA (1) CA2263388A1 (no)
CO (1) CO5031286A1 (no)
CZ (1) CZ46799A3 (no)
IL (1) IL128501A0 (no)
NO (2) NO312458B1 (no)
PL (1) PL331539A1 (no)
TR (1) TR199900318T2 (no)
TW (1) TW461878B (no)
WO (1) WO1998006397A1 (no)
ZA (1) ZA977301B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE226189T1 (de) 1996-05-24 2002-11-15 Neurosearch As Saure gruppen enthaltende phenylderivate, ihre herstellung und ihre verwendung als chloridkanalblocker
WO1997049400A1 (en) 1996-06-27 1997-12-31 Smithkline Beecham Corporation Il-8 receptor antagonists
US6335352B1 (en) * 1996-08-15 2002-01-01 Smithkline Beecham Corporation IL-8 receptor antagonists
CA2245224A1 (en) * 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
DE69914463T2 (de) * 1998-03-13 2004-11-11 The University Of British Columbia, Vancouver Therapeutische chemokine rezeptor antagonisten
AR029361A1 (es) * 1999-05-28 2003-06-25 Smithkline Beecham Corp Compuestos de guanidina ciclicas antagonistas de los receptores de la il- 8, composicion farmaceutica que los comprende y el uso de los mismos para la manufactura de un medicamento
AR029637A1 (es) * 1999-05-28 2003-07-10 Smithkline Beecham Corp Compuestos de guanidina, antagonistas de los receptores de la il-8, una composicion farmaceutica que los contiene y el uso de los mismos para la manufactura de un medicamento
ECSP003525A (es) * 1999-06-16 2002-01-25 Smithkline Beecham Corp Antagonistas del receptor de il- 8 iv
UY26627A1 (es) * 2000-03-24 2001-09-28 Smithkline Beecham Corp Antagonistas de receptores de il-8
US20050059584A1 (en) * 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
CA2335109A1 (en) * 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
US7378098B2 (en) * 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US7368425B2 (en) * 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
CN1423635A (zh) 2000-04-14 2003-06-11 吴羽化学工业株式会社 含氮化合物以及使用该化合物的抗病毒药
US6515001B2 (en) 2001-03-05 2003-02-04 Chemokine Therapeutic Corporation IL-8 receptor ligands-drugs for inflammatory and autoimmune diseases
EP1389460A1 (en) * 2001-05-24 2004-02-18 Kureha Chemical Industry Co., Ltd. Cxcr4-antagonistic drugs comprising nitrogen-containing compound
AU2003261974A1 (en) 2002-09-11 2004-04-30 Kureha Chemical Industry Company, Limited Amine compounds and use thereof
TW200418812A (en) * 2002-10-29 2004-10-01 Smithkline Beecham Corp IL-8 receptor antagonists
CA2558600C (en) * 2004-03-10 2013-07-09 Kureha Corporation A substituted-trialkyl amine compound with anti-viral activity based on antagonism against a chemokine receptor cxcr4
CA2565519A1 (en) 2004-05-12 2005-12-01 Schering Corporation Cxcr1 and cxcr2 chemokine antagonists
CA2576170A1 (en) 2004-08-16 2006-03-02 The Procter & Gamble Company 2-(amino or substituted amino)-5, 6-substituted phenol compounds, dyeing compositions containing them, and use thereof
EP1634573A1 (en) * 2004-08-16 2006-03-15 The Procter and Gamble Company 2-(Amino or substituted Amino)-5,6-substituted Phenol compounds, dyeing compositions containing them, and use thereof
WO2006043950A1 (en) * 2004-10-20 2006-04-27 Smithkline Beecham Corporation Il-8 receptor antagonists
EP2009992B1 (en) * 2006-04-21 2012-06-27 GlaxoSmithKline LLC Il-8 receptor antagonists
EP2010180A4 (en) * 2006-04-21 2010-10-13 Glaxosmithkline Llc IL-8 RECEPTOR ANTAGONISTS
CL2007001829A1 (es) * 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US537186A (en) * 1895-04-09 Jacob ebert
US4269837A (en) * 1980-02-19 1981-05-26 Pfizer Inc. Hypoglycemic guanylamidines, compositions and use
NZ229828A (en) * 1988-08-09 1992-03-26 Squibb & Sons Inc Aryl cyanoguanidine derivatives and pharmaceutical compositions
JP2742084B2 (ja) * 1989-03-13 1998-04-22 キヤノン株式会社 グアニジン二量化物およびグアニジン二量化物を含有する静電荷像現像用トナー
US5214208A (en) * 1989-03-13 1993-05-25 Canon Kabushiki Kaisha Toner containing a dimer of diarylguanidine type compound for developing electrostatic image
US5792444A (en) * 1989-05-09 1998-08-11 The General Hospital Corporation Labeled chemotactic peptides to image focal sites of infection or inflammation
US5371086A (en) * 1991-03-15 1994-12-06 The Green Cross Corporation Aminopyridine compounds
WO1994004499A1 (en) 1992-08-13 1994-03-03 The Upjohn Company Cyanoguanidines as potassium channel blockers
DK41193D0 (da) * 1993-04-07 1993-04-07 Neurosearch As Ionkanalaabnere
US5401758A (en) * 1993-10-07 1995-03-28 Bristol-Myers Squibb Company Pyridinyl cyanoguanidine compounds

Also Published As

Publication number Publication date
NO20016067L (no) 1999-04-12
BR9711140A (pt) 1999-08-17
TW461878B (en) 2001-11-01
AU4075097A (en) 1998-03-06
JP2000516619A (ja) 2000-12-12
PL331539A1 (en) 1999-07-19
CN1232398A (zh) 1999-10-20
AR008290A1 (es) 1999-12-29
CA2263388A1 (en) 1998-02-19
TR199900318T2 (xx) 1999-05-21
NO20016067D0 (no) 2001-12-12
IL128501A0 (en) 2000-01-31
EP0929302A4 (en) 2002-10-31
US6204294B1 (en) 2001-03-20
NO314301B1 (no) 2003-03-03
AU723816B2 (en) 2000-09-07
CO5031286A1 (es) 2001-04-27
WO1998006397A1 (en) 1998-02-19
EP0929302A1 (en) 1999-07-21
ZA977301B (en) 1998-02-16
CN1152675C (zh) 2004-06-09
NO312458B1 (no) 2002-05-13
NO990668D0 (no) 1999-02-12
CZ46799A3 (cs) 1999-12-15
KR20000030003A (ko) 2000-05-25

Similar Documents

Publication Publication Date Title
NO986110D0 (no) IL-8 reseptor-antagonister
NO986109D0 (no) IL-8 reseptor-antagonister
NO20001100D0 (no) IL-8 reseptorantagonister
NO983737L (no) IL-8 reseptor antagonister
NO990668L (no) IL-8 reseptor antagonister
DE69734833D1 (de) Vitronektin rezeptor antagonisten
DE69812096D1 (de) Neuropeptid y rezeptorantagonisten
EP0932405A4 (en) IL-8 RECEPTOR ANTAGONISTS
ID24726A (id) Antagonis-antagonis reseptor trombin
EP0907362A4 (en) IL-8 RECEPTOR ANTAGONISTS
EP1019035A4 (en) IL-8 RECEPTOR ANTAGONISTS
EP0920417A4 (en) IL-8 RECEPTOR ANTAGONISTS
DK0906294T3 (da) Benzoxazinon-dopamin D4-receptor-antagonister
ID24162A (id) Antagonis-antagonis reseptor vitronektin
DE69838874D1 (de) Il-8 rezeptor-antagonisten
DE69831413T2 (de) Il-8 rezeptor antagonisten
DE69824837D1 (de) Il-8-rezeptor-antagonisten
EP0923373A4 (en) IL-8 RECEPTOR ANTAGOISTS
EP0957907A4 (en) IL-8 RECEPTOR ANTAGONISTS
EP0939634A4 (en) IL-8 RECEPTOR ANTAGONISTS
EP0934066A4 (en) IL-8 RECEPTOR ANTAGONISTS
EP0920253A4 (en) IL-8 RECEPTOR ANTAGONISTS
EP0948330A4 (en) COOLING ANTENNA WITH CURVED SEGMENTS
NO20010353L (no) IL-8 reseptor-antagonist
TR199601082A3 (tr) Entegrin reseptör antagonistleri.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees